Innovative Bispecific Nanobody Targeting CD19 and CD3 for Next-Generation Cancer Immunotherapy
VHH-P570 is a humanized nanobody-based bispecific antibody fusion protein designed to target both the CD19 molecule (CD19) and the CD3 Complex (T Cell Receptor Complex). Currently in the Biological Testing stage, VHH-P570 leverages a modular architecture that enables simultaneous engagement of tumor cells and T cells, offering strong potential for the treatment of cancer. Its unique bispecific design aims to optimize immune cell redirection to malignant cells for enhanced anti-tumor activity. Developed with advanced recombinant technology and expressed in Expi293 cells, this candidate represents a promising approach in the rapidly evolving oncology landscape.
| Candidate | VHH-P570 |
| Target | CD19 molecule (CD19) CD3 Complex (T Cell Receptor Complex) |
| Modality | humanized bispecific VHH |
| Indication | Cancer |
Licensing Opportunity
VHH-P570 is available for out-licensing and collaborative development opportunities. We welcome inquiries from partners interested in advancing next-generation cancer immunotherapies built upon our bispecific nanobody platform.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P570 |
Modality
VHH-P570 is a bispecific antibody fusion protein constructed by combining a single chain variable fragment targeting CD19 with a single-domain antibody (nanobody) specific for CD3, further enhanced with an IgG1 Fc domain. The nanobody element imparts a compact structure and high stability, facilitating tissue penetration and prolonged circulation in vivo. The bispecific modality enables VHH-P570 to link tumor cells and T cells directly, improving immune synapse formation and cytotoxicity against cancer cells. These structural advantages are particularly valuable in oncology, where effective tumor infiltration and sustained immune engagement are critical for therapeutic success.
Target
CD19 and CD3 Complex are central to the mechanism of action of VHH-P570. CD19 is a transmembrane protein predominantly expressed on the surface of B cells, both normal and malignant, and serves as a hallmark of B cell lineage in various hematologic malignancies. The CD3 Complex, a critical component of the T cell receptor machinery, is expressed on T lymphocytes and is essential for T cell activation. By targeting CD19, VHH-P570 selectively binds malignant B cells, while engagement of CD3 Complex activates and redirects T cells towards tumor destruction. Together, these dual targets address key biological pathways in cancer immunology. Strategically, dual targeting of CD19 and CD3 Complex provides a robust approach for overcoming tumor resistance and enhancing anti-cancer immune responses.
Mechanism of Action
VHH-P570 functions as a T-cell engager by binding with dual specificity to CD19 on tumor cells and CD3 Complex on T cells. This bispecific interaction physically brings T cells into close proximity with malignant cells, facilitating efficient immune synapse formation and subsequent T cell activation. Upon engagement, T cells are induced to release cytolytic mediators, triggering apoptosis in targeted cancer cells. Additionally, the modular nanobody platform underpinning VHH-P570 supports future applications—including antibody-drug conjugates and diversified bispecific constructs—broadening potential utility across different tumor types and therapeutic modalities. The combined targeting of CD19 and CD3 Complex enables precise modulation of immune responses for optimized anti-tumor efficacy.
Cancer
Cancer comprises a broad spectrum of diseases characterized by uncontrolled cell growth and the ability to invade surrounding tissues or metastasize to distant sites. Collectively, cancer remains one of the leading causes of morbidity and mortality worldwide, with rising incidence rates attributed to aging populations and lifestyle factors. Standard treatments include surgery, chemotherapy, radiation therapy, immunotherapy, and targeted biological agents, each with varying efficacy and safety profiles. Despite significant advancements, limitations persist such as drug resistance, relapse, and adverse events, highlighting substantial unmet clinical needs. Novel approaches, such as bispecific T-cell engagers like VHH-P570, hold promise by harnessing the patient's own immune system to achieve targeted cytotoxicity while minimizing off-tumor effects. The differentiated mechanism and structural advantages of VHH-P570 may help address these challenges, offering a new solution for improving cancer patient outcomes.